---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-413217"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2026-10-05T12:30:07+00:00"
generated_at: "2026-10-12T14:46:18.084054+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome amends BMS license, pays $20M and 4,425,487 shares to end royalties and acquire patents

## Summary
- Immunome amended BMS license on Oct. 2, 2026, removing milestone/royalty obligations and assigning varegacestat (AL102) and AL101 patent rights to Immunome.
- Immunome paid BMS $20.0 million cash and issued 4,425,487 common shares; after payment, Immunome has no milestone, royalty or other payment obligations to BMS under the License Agreement.
- Stock Issuance Agreement requires Immunome to file a resale registration statement by Nov. 16, 2026, effective within 60 days or 5 business days if SEC does not review.
- The 4,425,487 shares were issued under Section 4(a)(2) exemption and were not registered under the Securities Act; BMS received resale registration rights.

## SEC filing metadata
- accession: 0001193125-26-413217
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2026-10-05T12:30:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/0001193125-26-413217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/d114908d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-413217
- JSON: https://secwatch.observer/filing/0001193125-26-413217.json
- Plain text: https://secwatch.observer/filing/0001193125-26-413217.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.